DIA Global
EVENTS
This webinar introduces the DIA Artificial Intelligence Consortium, a neutral, public‑private partnership that convenes regulators, biopharmaceutical companies, academia, and technology providers, including FDA, Health Canada, MHRA, PMDA, IQVIA, Gilead, Otsuka, BeOne Medicines, Beth Israel Deaconess Medical Center–Yale School of Medicine, and others.
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. Watch now.
NEWS
Main5 expert panel: Launch medications faster and at lower cost despite stricter formalities
JOBS
IN THE PRESS